Infections Helicobacter pylori

Excessive secretion of gastric acid, associated with Helicobacter pylori infection, can result in the development of gastric and duodenal ulcers small changes in the composition of bile can result in crystallization of cholesterol as gallstones failure of exocrine pancreatic secretion (as in cystic fibrosis) leads to undernutrition... [Pg.474]

Rathbone, B.J. and Heatley, R.V. (1992). Possible pathogenic mechanisms in Helicobacter pylori infection. In Helicobacter pylori and Gastroduodenal Disease (eds. B.J. Rathbone and R.V. Heatley) pp. 217-223. Blackwell Scientific Pubhcations, Oxford. [Pg.170]

Sobala, G.M., Crabtree, J., Dixon, M.F., Schorah, C.J., Taylor, J.D., Rathbone, B.J., Heatley, R.V. and Axon, A.T.R. (1991a). Acute Helicobacter pylori infection clinical features, local and systemic immune response, gastric mucosal histology and gastric juice ascorbic acid concentrations. Gut 32, 1415-1418. [Pg.171]

Helicobacter pylori infection and NSAID use account for most cases of PUD. The relatively high incidence of PUD in the elderly maybe due to higher NSAID use. Although hospitalizations related to PUD have decreased over the past two decades, the incidence of PUD-related complications such as bleeding and perforation remain unchanged. [Pg.270]

Chan FKL, Leung WK. Peptic ulcer disease. Lancet 2002 360 933-941. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad hoc committee on practice parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 93 2330-2338. [Pg.280]

Laheij RJ, Rossum LG, fanen fB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection a meta analysis. Aliment Pharmacol Ther 1999 13 857-864. [Pg.280]

Megraud F, Lamouliatte H. The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 1333-1343. Silverstein FE, Graham DY, Senior IR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 123 241-249. [Pg.280]

Suerbaum S, Micchetti P. Helicobacter pylori infection. N Engl I Med 2002 347 1175-1186. [Pg.280]

Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001 69[3] 158—168. [Pg.35]

Mahalanabis D, Rahman MM, Sarker SA, Bardhan PK, Hildebrand P, Beglinger C, et al Helicobacter pylori infection in the young in Bangladesh Prevalence, socioeconomic and nutritional aspects. Int J Epidemiol 1996 25 894-898. [Pg.19]

Lindkvist P, Asrat D, Nilsson I, Tsega E, Ols-son GL, Wretlind B, et al Age at acquisition of Helicobacter pylori infection Comparison of a high and a low prevalence country. Scand J Infect Dis 1996 28 181-184. [Pg.19]

Kawaguchi H, Haruma K, Komoto K, Yoshi-hara M, Sumii K, Kajiyama G Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 1996,91 959-962. [Pg.19]

Haruma K, Kamada T, Kawaguchi H, Okamo-to S, Yoshihara M, Sumii K, et al Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 2000 15 277-283. [Pg.19]

Rifaximin Rifamycin Antibiotic Gut bacteria Enteric infection Diarrhea, infectious Hepatic encephalopathy Small intestine bacterial overgrowth Inflammatory bowel disease Colonic diverticular disease Irritable bowel syndrome Constipation Clostridium difficile infection Helicobacter pylori infection Colorectal surgery Bowel decontamination, selective Pancreatitis, acute Bacterial peritonitis, spontaneous Nonsteroidal anti-inflammatory drug enteropathy... [Pg.36]

Bazzoli F, BianchiPorro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM Treatment of Helicobacter pylori infection. Indications and regimens An update. Dig Liver Dis 2002 34 70-83. [Pg.63]

Uemura N, Okamoto S, Yamamoto S, M atsu-mura N, Yamaguchi S, Yamakido M, Tan iya-ma K, Sasaki N, Schlemper RJ Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 345 784-789. [Pg.63]

Megraud F, Lamouliatte H The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 1333-1343. [Pg.64]

Parente F, Cucino C, Bianchi Porro G Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003 35 523-528. [Pg.64]

Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 553-560. [Pg.64]

Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A Rifabutin-based rescue therapy for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000 14 311—316. [Pg.64]

Zullo A, Hassan C, Campo S, Morini S Evolving therapy for Helicobacter pylori infection. Exp Opin Ther Patents 2004 14 1453-1464. [Pg.64]

Pretolani S, Bonvicini F, Brocci E, Cilia D, Pasini P, Baldini L, Epifanio G, Miglio F, Gasbarrini G Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection. Acta Gastroenterol Belg 1993 56 144A. [Pg.64]

Aging is one of the major risk factors for developing gastric ulcers because of an increased incidence of Helicobacter pylori infections and a widely spread use of non-steroidal anti-inflammatory drugs (NSAID). Co-morbidity, with the need for prophylactic medication with antiplatelet therapy, warfarin and other anticoagulants, also increases the risk of gastrointestinal bleeding and ulcerations (Murakami et al. 1968). [Pg.53]

Pilotto A (1996) Helicobacter pylori infection in the elderly. Clin Geriatr 4 53-70... [Pg.78]

Pilotto A, Franceschi M, Valerio G et al. (1999) Helicobacter pylori infection in elderly patients with peptic ulcer. Age Ageing 28(4) 412—414... [Pg.78]

Shibata, H., limuro, M., Uchiya, N., Kawamori, T., Nagaoka, M., Ueyama, S., Hashimoto, S., Yokokura, T., Sugimura, T., and Wakabayashi, K. (2003). Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter 8,59-65. [Pg.157]

Yamaoka, Y., Kita, M., Kodama, T., Imamura, S., Ohno, T., Sawai, N., Ishimaru, A., Imanishi, J., and Graham, D. Y. (2002). Helicobacter pylori infection in mice Role of outer membrane proteins in colonization and inflammation. Gastroenterology 123,1992-2004. [Pg.162]

McGee DJ, Mobley HE. 1999. Mechanisms of Helicobacter pylori infection bacterial factors. Cnrr Topics Microbiol Immnnol 241 155-180. [Pg.83]

Keywords Colon cancer functional dyspepsia functional gastrointestinal disorders gastroesophageal reflux disease Helicobacter pylori infection inflammatory bowel disease irritable bowel syndrome liver transplantation pharmacogenetics. [Pg.395]

Proton pump inhibitors (PPIs), such as omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, are commonly prescribed to treat symptoms of heartburn, acid reflux, chest pain, dyspepsia, and chronic cough. PPIs inhibit the transfer of protons into the stomach lumen. Pharmacological acid suppression is thus used to treat gastroesophageal reflux disease (GERD) and esophagitis, peptic ulcers, and Helicobacter pylori infection as well as to prevent ulcer development with concurrent nonsteroidal anti-inflammatory drug use. [Pg.396]

Gastroesophageal reflux disease (GERD), Helicobacter pylori infection... [Pg.406]

Pounder, R. E., and Ng, D. (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment. Pharmacol. Ther. 9, 33-39. [Pg.408]

See also in sourсe #XX -- [ Pg.36 ]

See also in sourсe #XX -- [ Pg.396 , Pg.406 ]

See also in sourсe #XX -- [ Pg.25 , Pg.43 , Pg.44 ]

See also in sourсe #XX -- [ Pg.439 ]

See also in sourсe #XX -- [ Pg.2873 ]

See also in sourсe #XX -- [ Pg.8 ]

See also in sourсe #XX -- [ Pg.8 ]

See also in sourсe #XX -- [ Pg.482 , Pg.483 , Pg.484 , Pg.485 , Pg.486 , Pg.487 , Pg.488 , Pg.489 , Pg.490 , Pg.491 , Pg.492 , Pg.493 , Pg.494 , Pg.495 , Pg.496 , Pg.497 , Pg.498 , Pg.499 , Pg.500 , Pg.501 , Pg.502 ]

See also in sourсe #XX -- [ Pg.344 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...